# US 2026/0297008 A1 · Reduced coenzyme q10 composition and production method for the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0297008 A1
- Document ID: US20260297008A1
- Status: Published application
- Kind: A1
- Application number: 19/659,329
- Filed: 2026-04-27
- Published: 2026-10-01
- Earliest claimed: 2025-03-31
- Assignees: Kaneka Corporation
- Applicants: Kaneka Corporation
- Inventors: Subaru Tanizaki; Tsuyoshi Matsuno; Takao Yamaguchi
- Web page: https://patentgrep.com/patent/US20260297008A1

## CPC

- C07C 49/84: containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups
- A61K 31/09: having two or more such linkages
- C07C 45/81: by change in the physical state, e.g. crystallisation
- C07C 45/86: Use of additives, e.g. for stabilisation
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A reduced coenzyme Q10 composition in which transition to other crystal forms is unlikely is provided. The reduced coenzyme Q10 composition includes reduced coenzyme Q10, reduced demethoxy Q10, and reduced coenzyme Q9. The peak area ratio (RD/RQ9) of a peak containing the reduced demethoxy Q10 (RD) having a relative retention time (RRT) relative to a retention time (RT) of a peak top of the reduced coenzyme Q10 of 0.88 to 0.94 to a peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in a chromatogram of the composition is 0.3 or more.

## Claims

### Claim 1

A reduced coenzyme Q10 composition comprising:
reduced coenzyme Q10,
reduced demethoxy Q10 (RD), and
reduced coenzyme Q9 (RQ9),
wherein a peak area ratio (RD/RQ9) of a peak containing the reduced demethoxy Q10 (RD) having a relative retention time (RRT) relative to a retention time (RT) of a peak top of the reduced coenzyme Q10 of 0.88 to 0.94 to a peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in a chromatogram of the composition is 0.3 or more,
wherein the chromatogram is obtained by high performance liquid chromatography under conditions in which
a column is a C18 column (150 mm in length and 4.6 mm in inner diameter),
a mobile phase composition is CH3OH:C6H14 at 9:1 (v/v),
a mobile phase flow rate is 1 mL/min, and
a detection wavelength is 190 nm.

### Claim 2 (depends on 1)

The reduced coenzyme Q10 composition according to claim 1, wherein the peak area ratio (RD/RQ9) is 1.0 or more.

### Claim 3 (depends on 1)

The reduced coenzyme Q10 composition according to claim 1, wherein the peak area ratio (RD/RQ9) is 2.0 to 8.0.

### Claim 4 (depends on 1)

The reduced coenzyme Q10 composition according to claim 1, further comprising decaprenylphenol.

### Claim 5 (depends on 4)

The reduced coenzyme Q10 composition according to claim 4, wherein a peak area ratio (decaprenylphenol/RQ9) of a peak containing the decaprenylphenol having the relative retention time (RRT) of 1.34 to 1.41 to the peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in the chromatogram of the composition is 0.1 to 10.0.

### Claim 6 (depends on 5)

The reduced coenzyme Q10 composition according to claim 5, wherein the peak area ratio (decaprenylphenol/RQ9) is 0.1 to 4.0.

### Claim 7 (depends on 5)

The reduced coenzyme Q10 composition according to claim 5, wherein the peak area ratio (decaprenylphenol/RQ9) is 1.0 to 4.0.

### Claim 8 (depends on 4)

The reduced coenzyme Q10 composition according to claim 4, further comprising reduced coenzyme Q11 (RQ11), wherein a peak area ratio (decaprenylphenol/RQ11) of a peak containing the decaprenylphenol having the relative retention time (RRT) of 1.34 to 1.41 to a peak containing the reduced coenzyme Q11 (RQ11) having the relative retention time (RRT) of 1.45 to 1.49 in the chromatogram of the composition is 0.01 to 1.5.

### Claim 9 (depends on 8)

The reduced coenzyme Q10 composition according to claim 8, wherein the peak area ratio (decaprenylphenol/RQ11) is 0.05 to 0.8.

### Claim 10 (depends on 8)

The reduced coenzyme Q10 composition according to claim 8, wherein the peak area ratio (decaprenylphenol/RQ11) is 0.1 to 0.5.

### Claim 11 (depends on 5)

The reduced coenzyme Q10 composition according to claim 5, further comprising reduced coenzyme Q11 (RQ11), wherein a peak area ratio (decaprenylphenol/RQ11) of the peak containing the decaprenylphenol having the relative retention time (RRT) of 1.34 to 1.41 to a peak containing the reduced coenzyme Q11 (RQ11) having the relative retention time (RRT) of 1.45 to 1.49 in the chromatogram of the composition is 0.01 to 1.5.

### Claim 12 (depends on 8)

The reduced coenzyme Q10 composition according to claim 8, wherein a peak area ratio (RQ11/RQ9) of the peak containing the reduced coenzyme Q11 (RQ11) having the relative retention time (RRT) of 1.45 to 1.49 to the peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in the chromatogram of the composition is 1.0 or more.

### Claim 13 (depends on 8)

The reduced coenzyme Q10 composition according to claim 8, wherein the peak area ratio (RQ11/RQ9) is 1.5 or more.

### Claim 14 (depends on 8)

The reduced coenzyme Q10 composition according to claim 8, wherein the peak area ratio (RQ11/RQ9) is 2.0 to 10.0.

### Claim 15 (depends on 11)

The reduced coenzyme Q10 composition according to claim 11, wherein a peak area ratio (RQ11/RQ9) of the peak containing the reduced coenzyme Q11 (RQ11) having the relative retention time (RRT) of 1.45 to 1.49 to the peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in the chromatogram of the composition is 1.0 or more.

### Claim 16 (depends on 1)

The reduced coenzyme Q10 composition according to claim 1, wherein the reduced coenzyme Q10 composition is in solid form.

### Claim 17 (depends on 1)

The reduced coenzyme Q10 composition according to claim 1, further comprising an antioxidant.

### Claim 18

A production method of reduced coenzyme Q10 composition comprising:
separating, from a solution comprising reduced coenzyme Q10, reduced demethoxy Q10 (RD), and reduced coenzyme Q9 (RQ9), a composition in solid form comprising the reduced coenzyme Q10, the reduced demethoxy Q10, and the reduced coenzyme Q9,
wherein a peak area ratio (RD/RQ9) of a peak containing the reduced demethoxy Q10 (RD) having a relative retention time (RRT) relative to a retention time (RT) of a peak top of the reduced coenzyme Q10 of 0.88 to 0.94 to a peak containing the reduced coenzyme Q9 (RQ9) having the relative retention time (RRT) of 0.69 to 0.73 in a chromatogram of the composition is 0.3 or more,
wherein the chromatogram of the composition after the separation is obtained by high performance liquid chromatography under conditions in which
a column is a C18 column (150 mm in length and 4.6 mm in inner diameter),
a mobile phase composition is CH3OH:C6H14 at 9:1 (v/v),
a mobile phase flow rate is 1 mL/min, and
a detection wavelength is 190 nm.

### Claim 19 (depends on 18)

The production method for the reduced coenzyme Q10 composition according to claim 18,
wherein the separating includes adding a seed crystal of reduced coenzyme Q10 to the solution and cooling the solution.
